Malignant melanoma is an aggressive cancer form with few treatment options and poor survival for patients with advanced disease. Increasing knowledge about molecular changes leading to development and progression of melanoma has identified the PI3K/Akt and MAPK/ERK1/2 pathways as frequently deregulated mediators of the malignant phenotype. Although considerable effort is made to therapeutically target these pathways, desired clinical results are yet to be obtained. For this reason there is still a need for more in depth dissection of these pathways and identification of novel downstream targets, which could hopefully lead to improvement of diagnostic methods and design of new and more efficient therapeutic strategies. With this in mind the aims of the present study were to:
1. Investigate activation status of the PI3K/Akt pathway in melanoma specimens and verify its significance in relation to clinicopathological parameters and patient outcome.
2. Identify and characterize new downstream targets of the PI3K/Akt and MAPK/ERK1/2 pathways involved in development and progression of melanoma.
List of Papers
I Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA: Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005 Oct;124(4):528-36. DOI: 10.1309/YT58WWMTA6YR1PRV
II Slipicevic A, Jørgensen K, Skrede M, Ree Rosnes AK, Trøen G, Davidson B and Flørenes VA: The fatty acid binding protein 7 (FABP7) is regulated independently by PKC and the MAPK/ERK pathway and is involved in proliferation and invasion of melanoma cells. BMC Cancer. 2008 Sep 30;8:276 DOI: 10.1186/1471-2407-8-276
III Øy GF, Slipicevic A, Davidson B, Solberg Faye R, Mælandsmo MG, Flørenes VA. Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer. 2009 Jul 8;126(2):350-361 DOI: 10.1002/ijc.24727